219 Terry Ave N
About Shape Therapeutics
Shape Therapeutics is a biotechnology company developing breakthrough gene therapy technologies to treat the world’s most challenging diseases. ShapeTX gene therapy platform comprises RNAskip™, RNAfix™, and RNAswitch™ payload technologies, next-generation tissue-specific AAVid™ delivery technology, and SquareBio, a solution to scalable gene therapy manufacturing based on industrialization of human stable cell lines. At the core of these technologies reside ShapeTX AI analytic platform, where data drives decisions in building technology today to enable gene therapies of tomorrow. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing life-long cures to patients. Shape Life!
At ShapeTX, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases.
Shape Therapeutics is headquartered in Seattle, Washington with a satellite site in Boston, Massachusetts.
ShapeTX - Tufts Launchpad Biolabs
75 Kneeland St. 14th floor
Boston, MA 02111
17 articles with Shape Therapeutics
Shape Therapeutics is evolving programmable RNA medicines that push the limits of current gene editing capabilities. BioSpace spoke with CSO David Huss.
Shape Therapeutics to Present Data Highlighting Advances in Its AI-Driven RNA Technology Platforms at the 2022 ASGCT Annual Meeting
Shape Therapeutics® Inc. the RNA technology company advancing programmable medicine, today announced new data from its RNAfix®, RNAskipTM and AAVidTM platforms will be presented at the 25th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on May 16-19, 2022 in Washington, D.C.
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
Shape Therapeutics Inc. will present virtually at the 40th Annual J.P. Morgan Healthcare Conference.
Shape Therapeutics Appoints David J. Huss, Ph.D., as Chief Scientific Officer and Lisa Taylor Ash, J.D., as General Counsel
Shape Therapeutics Inc. (ShapeTX), today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX.
Shape Therapeutics enters into a strategic research collaboration with Roche to advance breakthrough AAV-based RNA editing technology for neuroscience and rare disease indications
Shape Therapeutics Inc. today announced a multi-target strategic collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY).
Roche will apply RNAfix and Shape’s AAVid technology platform to develop next-generation tissue-specific adeno-associated viruses for new gene therapies aimed at these indications.
7/21/2021More money means more progress for potentially life-saving therapies. Here's a peek at some biopharma companies adding to their books this week.
The amount is intended to support the company's growing portfolio of RNA technologies and accelerate efforts to develop various treatment approaches in the gene therapy field.
Shape Therapeutics Secures $112 Million in Series B Financing to Advance Breakthrough RNA Technology Platforms to Democratize Gene Therapy
Shape Therapeutics Inc. today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital.
Shape Therapeutics to Present the Discovery of Muscle-Specific AAVs at the Jefferies 2021 Virtual Healthcare Conference
Shape Therapeutics Inc., a biotechnology company developing breakthrough technologies to enable gene therapy for all, announced that Francois Vignealt, PhD, President and Chief Executive Officer, is scheduled to present virtually at the Jefferies 2021 Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:00 p.m. Eastern Time.
Shape Therapeutics Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, today announced two abstracts have been accepted for digital presentation at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, taking place virtually May 11-14, 2021.
Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer.
Shape Therapeutics to Highlight RNA Editing Technology Platform Advancements in Parkinson’s Disease and the Identification of Novel CNS-targeting AAV Variants at the J.P. Morgan 39th Annual Healthcare Conference
Shape Therapeutics Inc. (ShapeTX), a next-generation RNA-targeting gene therapy company, announces today the upcoming company presentation at the J.P. Morgan 39th Annual Healthcare Conference by Francois Vigneault, PhD., President and Chief Executive Officer.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the appointment of Gary Fortin as Chief Operating Officer (COO). Prior to joining ShapeTX, Dr. Fortin was Head of Business Strategy and Operations for the Severe Genetic Disease unit of bluebird bio (NASDAQ:BLUE), where he navigated a portfolio of gene therapy programs through
Shape Therapeutics Unveils AAVid™ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene Therapy
Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the unveiling of the AAVidTM capsid discovery platform and results from its first AAV5 variant library in a non-human primate selection campaign.